Key Takeaways
- Base business margins surge past target: Base business adjusted EBITDA margin hit 37% in Q2, well above the 35% target, driven by favorable product mix and operational efficiencies.
- Cenexi turnaround on track, breakeven promised: Cenexi losses halved YoY to EUR 5 million in H1, and management reaffirmed its commitment to reach EBITDA breakeven in Q3 FY26.
- U.S. growth broad-based, not price-led: U.S. revenue grew 8% YoY with price nearly flat; volume contributed +10% and new launches added +7%, showing the engine is volume and innovation-driven.
- GLP-1 capacity build signals big ambition: With 4 crore capacity now filled and another 10 crore being built, Gland aims to be a top-tier cartridge capacity by mid-next year, targeting semaglutide launches as patents open.
- What to watch next quarter: Whether Cenexi actually hits EBITDA breakeven, the pace of GLP-1 contract signings, and if milestone revenue recovers from its Q2 trough.
Base Business Margin Expansion
- Gross margin leap: Base business gross margins improved to 61% in Q2 from 56% a year ago, and 60% in H1 from 54%, supported by favorable business and product mix.
- Operational efficiency compounding: Margins have improved quarter-on-quarter for three to four quarters through automation of lines, input material optimization, batch size improvements, and bottleneck automation.
- Profit share richer than normal: Profit share reached 13% versus a normal 9-10% because recently launched products carry higher contribution margins than the legacy portfolio.
- Milestone revenue dipped on timing and caution: Milestone revenue was only ~₹44-45 crore versus a normal ~₹75-80 crore, partly because U.S. partners slowed licensing decisions to wait and see on policy, and partly due to quarter-to-quarter lumpiness. Management expects a bump-up in coming quarters.
- R&D spend elevated but intentional: R&D expense rose to 6% of revenue this quarter due to six filings and a more complex, more expensive portfolio; the full-year expectation is around 5%.
Srinivas Sadu: "If you have seen last three to four quarters, we are actually improving our margins quarter-on-quarter basis because of the initiatives we have taken both from automation of lines, also from input materials and also from the operational efficiencies' perspective, working on the batch sizes and also looking at the bottlenecks where we can automate smaller things."
Cenexi Turnaround
- Losses halved, trajectory improving: Cenexi H1 FY26 revenue grew 10% YoY to EUR 88 million while EBITDA losses halved to EUR 5 million from EUR 11 million, demonstrating the turnaround strategy is taking effect.
- Q2 loss was planned, not structural: Q2 revenue of EUR 40 million grew 8% but losses were incurred due to a planned operational shutdown; the underlying trend is improvement.
- Site-level recovery visible: Activity at Hérouville increased significantly, driven by ramp-up of an inactivated vaccine and a sterile ophthalmic gel. Braine-l'Alleud is qualifying two new freeze dryers, expected by end of 2025.
- Fontenay regulatory risk retired: GMP certification was renewed through end of 2026, and most ANSM observations have been addressed, with progress reviewed during a routine July inspection.
- Transformation levers in motion: Headcount optimization, price increases, creation of a back office in India for finance and IT, and capacity enhancement are all ongoing.
- Breakeven threshold quantified: If Cenexi hits the EUR 50 million quarterly revenue target from Q3, it will be EBITDA positive; management said even a couple of million lower could achieve breakeven.
Srinivas Sadu: "No, no, we do stick to that breakeven guidance for this quarter [Q3FY26]."
U.S. Business: Volume and Innovation-Led Growth
- Growth composition is healthy: U.S. revenue grew 8% YoY to ₹800.5 crore in Q2. Price was almost flat versus the prior quarter; volume contributed +10% and new launches added +7%.
- Concentration is working in Gland's favor: The top 20 molecules grew 9%, the top 10 molecules grew 14%, and the top 10 customers grew approximately 19%, indicating deepening relationships and share gains in key products.
- Seven launches this quarter: New products included Daptomycin-RTU, Sumatriptan, and a new strength of Colistimethate.
- RTU bag portfolio building: 20 RTU bag products have been filed in the U.S., 14 are already approved, and 10 more are in development. Initial market share for RTU products is expected at 15-20%, increasing once GPO contracts open.
- Complex pipeline advancing: 15 products are under active development: 7 via the 505(b)(2) pathway and 8 as ANDAs.
- Dalbavancin launch imminent: The goal date is this month (November 2025); revenue is expected this quarter and next, with an initially larger quantity pickup for pipeline filling before normalization.
- Colistimethate project secured: An on-market product tech transfer from Xellia, worth almost ₹150 crore, with a dedicated line starting next quarter.
Srinivas Sadu: "If you look at the growth which came from last quarter also are from the launches, what we've done on the Specialty segment, CDMO launches that we have done, whether it's auto injectors or pendevice systems."
GLP-1 and Biologics Capacity Build
- Cartridge capacity tripling: Current capacity of 4 crore units is now filled; another 10 crore capacity is being built, taking total cartridge capacity to 14 crore by mid-next year. Management says this makes Gland one of the top-tier capacities.
- Semaglutide opportunity approaching: Sema patents open next year in some markets; Gland will start supplying to those markets if it secures approvals.
- Ramp-up will take two years: The 4 crore capacity will take approximately two years to fully ramp up from early next year, driven by a combination of liraglutide, semaglutide, and other projects.
- First GLP-1 partner launched: Liraglutide supply has begun, with the 4 crore capacity up and running. Two more GLP-1 contracts are in the process of being signed.
- Biologics CDMO expansion planned: Intent to expand from 8 KL to 23 KL; collaboration discussions are ongoing with companies in India and outside India. The biologics plant has started generating revenue through the Dr. Reddy's arrangement.
Shyamakant Giri: "So by mid of next year, we'll be having 14 crore capacity on cartridges, which makes us one of the top tier capacities here."
ROW and Other Markets
- ROW flat but product sales growing: Overall ROW was flat in H1, but this masks a sharp divergence: own product sales grew 19% across Latam, Southeast Asia, Africa, and the Middle East, while tech transfer and CMO product revenue declined 53%.
- CMO recovery expected with a lag: The CMO and tech transfer business will increase but will take a couple of quarters to come to the top line.
- Daptomycin timing issue in Europe: A timing-related softness in Europe is expected to correct in the quarters ahead.
- Enoxaparin supply to Civica started: This was one of the growth levers flagged last quarter and has now begun contributing.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cenexi EBITDA breakeven | EBITDA positive at EUR 50 million quarterly revenue; possibly breakeven at slightly lower revenue | Q3 FY26 |
| Consolidated revenue growth | Mid-teens growth on a consolidated basis | FY26 |
| Base business EBITDA margin | Targeting around 35%; currently at 37% | Ongoing |
| Consolidated gross margin | 74-75% on a sustainable basis | FY26 full year |
| R&D expense | Around 5% of revenue | Annual basis |
| Base business capex | Approximately ₹250 crore | FY26 |
| Base business capex | Approximately ₹300 crore | FY27 |
| GLP-1 cartridge capacity | 14 crore units | By mid-next year |
| GLP-1 4 crore capacity ramp-up | Full utilization | Approximately 2 years from early next year |
| Biologics CDMO capacity | Expansion from 8 KL to 23 KL | Next phase (undated) |
| Braine-l'Alleud freeze dryers | Qualification of two new freeze dryers completed | End of 2025 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated revenue | ₹1,486.9 crore, up 6% YoY |
| Consolidated EBITDA | ₹313.9 crore, up 6% YoY |
| Consolidated EBITDA margin | 21% |
| Consolidated net profit | ₹183.7 crore, PAT margin 12%, in line with Q2 FY25 |
| Base business (ex-Cenexi) revenue | ₹1,076.7 crore |
| Base business adjusted EBITDA margin | 37% |
| U.S. revenue | ₹800.5 crore, up 8% YoY |
| Cenexi revenue | €40 million, up 8% YoY; ₹410.2 crore, up 21% YoY in rupee terms |
| Cenexi H1 FY26 EBITDA loss | €5 million, decreased from €11 million in H1 FY25 |
| Consolidated gross margin | 63%, up from 59% in Q2 FY25 |
| Base business gross margin | 61%, up from 56% in Q2 FY25 |
| R&D expense | ₹61.4 crore, 5.8% of revenue, up from ₹49.3 crore in Q2 FY25 |
| Other income | ₹84.2 crore, primarily from forex gains and interest on bank deposits |
| Cash flows from operations | ₹331.2 crore |
| Total cash and equivalents (group level, as of Sep 30, 2025) | ₹3,099.9 crore, including non-callable deposits of ₹396 crore |
| External debt at Cenexi level (as of Sep 30, 2025) | ₹254.4 crore |
| Average cash conversion cycle (H1 FY26) | 163 days, improved from 172 days at end of FY25 |
| Capex (H1 FY26) | ₹196.9 crore, mainly deployed in Cenexi for new projects and capacity building |
| ANDAs filed in the quarter | 6 |
| ANDA approvals received in the quarter | 5 |
| New products launched in the U.S. in the quarter | 7 |
| RTU bag products filed in the U.S. | 20 filed, 14 approved, 10 more in development, targeting an opportunity of roughly $659 million |
| Products under active development in high-potential categories | 15, including 7 505(b)(2) and 8 ANDAs |
| Biologic CDMO facility current capacity | 8 KL, with plan to expand to 23 KL |
| Cartridge fill/finish capacity expansion | Increasing from 4 crore to 14 crore units |
| Cenexi new project wins in the quarter | 4 |
| Milestone revenue in the quarter | ~₹44-45 crore, versus a normal run rate of ~₹75-80 crore |
| Profit share for the quarter | 13%, compared to a general range of 9% to 10% |
| U.S. business volume growth (QoQ) | 10%, price almost flat, new launch contribution 7% |
| ROW own product sales growth (H1 FY26) | 19%, while tech transfer and CMO product revenue declined 53% |
| Standalone effective tax rate | 26% |
| Expected capex for Gland base business (full year FY26) | Approximately ₹250 crore |
| Expected capex for Gland base business (FY27) | Approximately ₹300 crore |